December 13, 2012
5 PM in Mainz, Germany
TRON – Building 708 at University Medical Center Mainz
Prof. Dr. Ada Kruisbeek
Founder and CSO of DCPrime BV, Leiden, Netherlands
“Challenges and opportunities of a next generation dendritic cell cancer vaccine: pre-clinical and clinical overview”
Ada Kruisbeek is an immunologist whose career has been dedicated to gaining insights into how the immune system is regulated, and in translating scientific discoveries in that field into novel immunotherapeutics, in particular against cancer. She founded DCPrime in 2006 and is currently responsible for the overall scientific agenda. She has more than 30 years of managerial experience in science and business, first in academic settings, and later in industry. After she obtained her PhD, Ada worked at the National Cancer Institute at the National Institutes of Health, Bethesda, MD, USA, from 1978 until 1992, at the forefront of research that revealed how the immune system develops. She then became Head of the Department of Immunology at the Nederlands Kanker Instituut-Antoni van Leeuwenhoekhuis (NKI-AVL) in Amsterdam from 1992 till 2001. She published over 140 papers, many of which appeared in peer-reviewed top-journals such as Immunity, Nature, Science, PNAS and the Journal of Experimental Medicine.
She became a professor of Molecular Immunology in 1993, and of Knowledge Valorization in 2010. She also served on multiple advisory boards of national and international scientific agencies, research institutes and companies, and on many editorial boards. In 2001, she moved to industry and became Senior Vice-President Research at Crucell BV, responsible for building up the cancer antibody pipeline. In 2004, when Crucell closed its oncology programs, Ada moved to the Vrije Universiteit (VU) in Amsterdam and became the Director of the Cancer Center Amsterdam. She went on to found the Technology Transfer Office (TTO) for the VU & VUmc in 2005, DCPrime in 2006, and the Life Sciences Center Amsterdam in 2007.
In less than 5 years, she succeeded in making DCPrime a clinical stage company, dedicated to developing the first dendritic cell platform for generating off-the-shelf DC-based vaccines. DCPrime closed its first financing round in September 2010.